Amarillo Completes Enrollment In Influenza Phase 2 Clinical Trial

Amarillo has completed the enrollment procedure in a Phase 2 clinical study of the oral interferon product at the University of Western Australia.

The company said that a total of 200 healthy volunteers have been enrolled to 16 weeks of treatment with oral interferon or matching placebo.

The double-blind clinical trial is expected to show the effectiveness of lozenges containing a low dose of interferon-alpha. The trial is to find out if lozenges can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses, when taken once a day during a typical winter cold/flu season.

The final study results are expected to be available before the end of the year, said the company.